Journal
BRAIN PATHOLOGY
Volume 32, Issue 4, Pages -Publisher
WILEY
DOI: 10.1111/bpa.13037
Keywords
angiomatoid fibrous histiocytoma (AFH); ATF1; brain tumor; clear cell sarcoma; CREB1; CREM; EWSR1; intracranial mesenchymal tumor with FET-CREB fusion; intracranial myxoid mesenchymal tumor; molecular neuropathology; sarcoma
Categories
Funding
- NIH Director's Early Independence Award from the Office of the Director, National Institutes of Health [DP5 OD021403]
- UCSF Brain Tumor SPORE from the National Cancer Institute, National Institutes of Health [P50 CA097257]
- Morgan Adams Foundation
- Yuvaan Tiwari Foundation
- Sandler Foundation
Ask authors/readers for more resources
Intracranial mesenchymal tumor, FET-CREB fusion-positive can be categorized into two distinct epigenetic subgroups with unique clinical and molecular features, as well as different survival outcomes. This may assist in more accurate diagnosis and treatment of this unique tumor entity.
'Intracranial mesenchymal tumor, FET-CREB fusion-positive' occurs primarily in children and young adults and has previously been termed intracranial angiomatoid fibrous histiocytoma (AFH) or intracranial myxoid mesenchymal tumor (IMMT). Here we performed genome-wide DNA methylation array profiling of 20 primary intracranial mesenchymal tumors with FET-CREB fusion to further study their ontology. These tumors resolved into two distinct epigenetic subgroups that were both divergent from all other analyzed intracranial neoplasms and soft tissue sarcomas, including meningioma, clear cell sarcoma of soft tissue (CCS), and AFH of extracranial soft tissue. The first subgroup (Group A, 16 tumors) clustered nearest to but independent of solitary fibrous tumor and AFH of extracranial soft tissue, whereas the second epigenetic subgroup (Group B, 4 tumors) clustered nearest to but independent of CCS and also lacked expression of melanocytic markers (HMB45, Melan A, or MITF) characteristic of CCS. Group A tumors most often occurred in adolescence or early adulthood, arose throughout the neuroaxis, and contained mostly EWSR1-ATF1 and EWSR1-CREB1 fusions. Group B tumors arose most often in early childhood, were located along the cerebral convexities or spinal cord, and demonstrated an enrichment for tumors with CREM as the fusion partner (either EWSR1-CREM or FUS-CREM). Group A tumors more often demonstrated stellate/spindle cell morphology and hemangioma-like vasculature, whereas Group B tumors more often demonstrated round cell or epithelioid/rhabdoid morphology without hemangioma-like vasculature, although robust comparison of these clinical and histologic features requires future study. Patients with Group B tumors had inferior progression-free survival relative to Group A tumors (median 4.5 vs. 49 months, p = 0.001). Together, these findings confirm that intracranial AFH-like neoplasms and IMMT represent histologic variants of a single tumor type ('intracranial mesenchymal tumor, FET-CREB fusion-positive') that is distinct from meningioma and extracranial sarcomas. Additionally, epigenomic evaluation may provide important prognostic subtyping for this unique tumor entity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available